WISCONSIN DRUG UTILIZATION REVIEW BOARD

Department Guidelines

2025

Contents

. DUR Board Bylaws	. 2
A. Legal Authority	. 2
B. Composition and Membership	. 2
C. Terms of Office	
D. Replacement of Members	. 2
E. Quorum	
F. Duties and Responsibilities	.2
1. Administrative	. 2
2. Professional	.3
G. Meetings	.3
H. Confidentiality and Immunity	.3
I. Conflict of Interest	.3
II. Wisconsin Medicaid Drug Utilization Review Confidentiality and Conflict of Interest Statement	2

I. DUR Board Bylaws

A. Legal Authority

Pursuant to the Omnibus Budget Reconciliation Act of 1990 (OBRA '90), federal rules, 42 CFR 456.716, require that the state Medicaid agency establish a Drug Utilization Review (DUR) program. The DUR program is charged with developing procedures to assure drug use are appropriate, medically necessary and are unlikely to result in adverse medical results.

B. Composition and Membership

At least one-third but no more than 51 percent of the DUR Board members must be physicians and at least one-third of the board members must be pharmacists. All professional members must be actively practicing and licensed to practice in the State of Wisconsin.

DUR Board members must have recognized knowledge and expertise in at least one of the following:

- Clinically appropriate prescribing of covered outpatient drugs.
- Clinically appropriate dispensing and monitoring of covered outpatient drugs.
- Drug use review, evaluation and intervention.
- Medical quality assurance.

The DUR Pharmacist Consultant shall be staff to the Board as shall any members designated by the Division of Medicaid Services (DMS) Department of Health Services (DHS), State of Wisconsin.

DMS shall solicit recommendations for Board membership through the Wisconsin Medical Society, the Pharmacy Society of Wisconsin, the University of Wisconsin-School of Pharmacy and current Board member recommendations. Potential members will be recommended to the Division Administration.

C. Terms of Office

Board members will be appointed for a three-year term and may be reappointed for additional terms. Terms will be staggered.

D. Replacement of Members

If a vacancy is created by the resignation of a member, the DMS will solicit recommendations through the appropriate agencies and appoint an individual to fill the unexpired term.

Two (2) unexcused (i.e., does not RSVP to meetings, does not use Board member specific meeting link) consecutive absences from scheduled meetings shall constitute a resignation.

E. Quorum

For purposes of voting and other official action, a quorum shall be declared if at least 50 percent of the voting members are present.

F. Duties and Responsibilities

1. Administrative

The DUR contractor will perform the following administrative functions including:

- Coordination of meetings; and
- Record keeping including preparation of the minutes.

2. Professional

The DUR Board activities shall include but not limited to the following:

- Review and make recommendations to the DMS based on federally predetermined standards for retrospective and prospective DUR;
- Approve ongoing educational interventions for physicians and pharmacists, targeted toward cost effective prescribing, therapy problems, or individuals identified in the course of drug use reviews;
- Oversee the operation of the DUR program; and
- Actively participate (e.g., partake in topic discussions, voting, etc.) during the DUR Board meetings.

G. Meetings

Meetings will be held at least four (4) times annually. Meetings are held virtually, unless otherwise deemed necessary and/or appropriate to meet in person. DUR Board members shall use the meeting invitation meeting link that is specific to the Board member to actively participate in the meeting. DUR Board members shall not use the public meeting link as this link does not allow the Board member to actively participate in the meeting.

H. Confidentiality and Immunity

Annually, all DUR Board members will be required to sign the Wisconsin Medicaid Drug Utilization Review Confidentiality and Conflict of Interest statement in which the member agrees not to use, distribute or disclose information regarding any member, provider or case reviewed by the DUR Board. The Board member must also agree that any information discussed at the DUR Board meeting will not be disclosed in a manner which could identify the views of the specific members of the DUR Board. The DUR Board member forfeits voting rights until the statement is signed and submitted to DMS.

All DUR Board members are entitled to the same immunities from civil liability as a result of acts or omissions in rendering service as a member of the DUR Board as are enjoyed by state employees and officials for acts within the scope of their employment.

I. Conflict of Interest

A conflict of interest shall exist when the member has an existing or potential personal, professional or monetary interest, or when a member's spouse or child has an existing or potential monetary interest, in a matter under consideration by the DUR Board. A member shall disclose any potential conflict in writing at the time of their appointment to the Board and at the commencement of consideration of substantive matters before the Board, or at the point when the conflict of interest becomes apparent in discussion or deliberation of the matter and shall abstain from any vote in the matter. Minutes of the meeting will reflect the conflict of interest and that abstention from voting had occurred. In the event there are questions as to whether a conflict of interest or potential conflict of interest exists in a case of an individual member, the question shall be decided by the DMS Division Administrator.

Members shall not represent themselves as officers or employees of the State of Wisconsin when acting as a DUR Board member.

II. Wisconsin Medicaid Drug Utilization Review Confidentiality and Conflict of Interest Statement

Information about any Medicaid recipient is confidential and may be used or disclosed only for purposes directly related to Medicaid administration, as determined by the State Medicaid Agency. No member of

the Wisconsin Medicaid Drug Utilization Review Committee ("Committee") may disclose to any person any information regarding any Medicaid recipient.

Some information not related to Medicaid recipients that members of the Committee may obtain in the course of their participation on the Committee may qualify as trade secret under Wisconsin law. Such information will be clearly identified as such. No member may disclose any trade secret information obtained in the course of participation to the Chair/Medicaid Director.

A member of the Committee shall disclose a conflict of interest at the beginning of consideration of any matter in which the member has or may have a conflict of interest, or at the point during consideration when a potential conflict of interest becomes apparent to the member. After disclosure, the member may continue to participate in discussion but shall abstain in any vote taken. Minutes of the meeting will reflect the disclosure and abstention from voting. Any question as to whether a conflict of interest exists shall be referred to the Chair/Medicaid Director.

A conflict of interest exists whenever:

- You, a member of your immediate family, or an organization with which you are associated has a substantial financial interest in the outcome of matter; or
- The outcome of a matter may produce or assist in producing a substantial financial benefit, direct
 or indirect, for you, one or more of your immediate family, or an organization with which you are
 associated; or
- You, a member of your immediate family, or an organization with which you are associated receive money or any other thing of value from a company or other organization that has financial interest in the outcome of a matter.

"Immediate family" includes your spouse and any relative by marriage, lineal descent or adoption who receives more than one-half of his or her support from you or from whom you receive more than one-half of your support.

"Organization with which you are associated" includes any organization in which you or a member of your immediate family is a director, officer or trustee, or owns or controls, directly or indirectly, at least 10 percent of the outstanding equity or of which you or a member of your immediate family is an authorized representative or agent.